Behavioural characterisation of ORM (Orion Pharma NCE) and Pregabalin in the Streptozotocin model of diabetes induced neuropathic pain

Project: Consultancy

Project Details

Key findings

A novel TRPA1 antagonist dependently reversed allodynia in STZ neuropathic pain model.
PK PD was established.
This provides novel data to broaden our understanding on blocking this mechanism (TRPA1) in our diabetes neuropathic pain model and Identifies the potential of targeting TRPA1 receptors in diabetic neuropathic pain.
Effective start/end date20/08/1410/10/14


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.